4-甲基-1-哌嗪磺酰氯 | 1688-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-甲基-1-哌嗪磺酰氯
• 中文别名: 4-甲基哌嗪-1-磺酰氯
• 英文名称: 4-methylpiperazine-1-sulfonyl chloride
• 英文别名: 4-methyl-piperazin-1-ylsulphonyl chloride
• CAS: 1688-95-5
• 化学式: C₅H₁₁ClN₂O₂S
• 分子量: 198.674
• InChiKey: GDYYZWFHNRVHCC-UHFFFAOYSA-N

物化性质

• 沸点：
  282.1±29.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H314
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Methylpiperazine-1-sulfonyl chloride
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Methylpiperazine-1-sulfonyl chloride
CAS number: 1688-95-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H11ClN2O2S
Molecular weight: 198.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲基-1-哌嗪磺酰氯 在 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成 4-甲基-1-哌嗪磺酰胺
  参考文献：
  名称：

  新型酰基磺酰胺类有效和选择性Bcl-2抑制剂的设计，合成和药理学评估

  摘要：

  在许多肿瘤细胞中过表达的抗凋亡蛋白Bcl-2是潜在的小分子抗癌药物发现的有吸引力的靶标。在这里，我们报告了通过将哌嗪基-苯基片段合并到一个双环框架中而导致一系列新型类似物的对ABT-263的不同结构修饰方法，其中四氢异喹啉13对Bcl-2的作用几乎与ABT-263相同。P4相互作用口袋中的进一步SAR修饰了二氟氮杂环丁烷取代的类似物55，该类似物保留了良好的Bcl-2活性，并具有改善的Bcl-2 / Bcl-xL选择性。

  DOI：

  10.1016/j.bmc.2017.12.001
• 作为产物：
  描述：

  N-甲基哌嗪 在 磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-甲基-1-哌嗪磺酰氯
  参考文献：
  名称：

  一系列带有磺胺支架的核苷衍生物作为有效和选择性 PRMT5 抑制剂的构效关系研究

  摘要：

  蛋白精氨酸甲基转移酶 5 (PRMT5) 是治疗恶性肿瘤的有前途的靶点。使用新型支架发现核苷衍生的 PRMT5 抑制剂一直具有挑战性。在此，我们报告了我们在设计和合成带有磺胺支架的核苷衍生物作为有效的 PRMT5 抑制剂方面所做的努力。代表性化合物23n被鉴定为有效且选择性的 PRMT5 抑制剂，IC 50值为 8 nM。分子对接研究证明了化合物23n的结合模式，并说明了其对 PRMT5 的抑制活性。三甲基锁前药策略用于提供具有较低极性的前药36，可以快速释放活性化合物23n进入肿瘤细胞后。基于细胞的测定表明，前药36比23n更有效地抑制 Z-138 和 MOLM-13 细胞的增殖并抑制 PRMT5 底物的甲基化。此外，化合物23n和36主要通过有效诱导细胞凋亡而不是阻滞细胞周期对Z-138细胞发挥抗增殖作用。因此，化合物23n和36代表了一系列具有新型支架的有效 PRMT5 抑制剂。

  DOI：

  10.1016/j.bioorg.2022.106228

文献信息

• Method and compositions for identifying anti-HIV therapeutic compounds
  申请人：GILEAD SCIENCES, INC.

  公开号：US20040121316A1

  公开（公告）日：2004-06-24

  Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

  提供了一种鉴定含有羧酸酯或磷酸酯基团抗HIV治疗化合物的方法。可以选择使用新型酶GS-7340酯水解酶筛选这类化合物的文库。还提供了与GS-7340酯水解酶相关的组合物和方法。
• A Novel Class of<i>N</i>‐Sulfonyl and<i>N</i>‐Sulfamoyl Noscapine Derivatives that Promote Mitotic Arrest in Cancer Cells
  作者：Cassandra Yong、Shane M. Devine、Xuexin Gao、Angelina Yan、Richard Callaghan、Ben Capuano、Peter J. Scammells

  DOI：10.1002/cmdc.201900477

  日期：2019.12.4

  synthesis and pharmacological evaluation of a series of N-sulfonyl and N-sulfamoyl noscapine derivatives. A number of these sulfonyl-containing noscapinoids demonstrated improved activities compared to noscapine. ((R)-5-((S)-4,5-Dimethoxy-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-((1-methyl-1H-imidazol-4-yl)sulfonyl)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline) (14 q) displayed sub-micromolar activities

  Noscapine显示出较弱的抗癌功效，许多研究工作已尝试生成更有效的Noscapine类似物。这些修饰包括用一系列取代基取代6'-位的N-甲基，其中观察到N-乙基氨基甲酰基取代具有增强的抗癌活性。本文中，我们描述了该领域的进展，即一系列N-磺酰基和N-氨磺酰基Noscapine衍生物的合成和药理学评价。与Noscapine相比，许多这些含磺酰基的Noscapinoids表现出改善的活性。（（R）-5-（（S）-4,5-二甲氧基-1,3-二氢异苯并呋喃-1-基）-4-甲氧基-6-（（1-甲基-1H-咪唑-4-基）磺酰基）-5,6,7,8-四氢[1,3] dioxolo [4,5-g]异喹啉）（14 q）表现出对MCF-7的560、980、271和443 nM亚微摩尔活性，分别为PANC-1，MDA-MB-435和SK-MEL-5电池。尽管多药外排泵P-糖蛋白高表达，但这种抗增殖作用仍可抵抗耐药的NCI
• 2-AMINOQUINOLINES
  申请人：Kolczewski Sabine

  公开号：US20090227570A1

  公开（公告）日：2009-09-10

  The present invention is concerned with 2-aminoquinoline derivatives of formula I where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, and n are as defined in the specification and claims, their use 5-HT 5A receptor antagonists, their manufacture, and pharmaceutical compositions containing them.

  本发明涉及式I的2-氨基喹啉衍生物，其中R1、R2、R3、R4、R5、R6、A和n如规范和声明中定义，它们用作5-HT5A受体拮抗剂，它们的制造以及含有它们的药物组合物。
• Photoredox-Catalyzed Generation of Sulfamyl Radicals: Sulfonamidation of Enol Silyl Ether with Chlorosulfonamide
  作者：Qiyu Luo、Runyu Mao、Yan Zhu、Yonghui Wang

  DOI：10.1021/acs.joc.9b02062

  日期：2019.11.1

  A novel and practical photoredox-catalyzed generation of sulfamyl radicals followed by radical sulfonamidation of enol silyl ether has been described. Diverse functionalized β-ketosulfonamides were prepared in modest to excellent yields under mild and economic reaction conditions through the present catalytic protocol. Furthermore, the methodology developed provides an efficient and convenient approach

  已经描述了新颖且实用的光氧化还原催化的磺酰胺基的产生，随后是烯醇甲硅烷基醚的自由基磺酰胺化。通过本发明的催化方案，在温和且经济的反应条件下以适度至优异的产率制备了多种官能化的β-酮磺酰胺。此外，开发的方法为合成抗癫痫药Zonisamide提供了一种有效而便捷的方法。
• [EN] PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLO[2,3-B]PYRIDINE CDK9 KINASE
  申请人：ABBVIE INC

  公开号：WO2014139328A1

  公开（公告）日：2014-09-18

  Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

  公开的是Formula (IIa)的化合物，其中R1、R2、R3A、R3B、R3C、R3D、R3E和R4如规范中所定义，并且其药用盐。这些化合物可用作治疗疾病，包括癌症的药物。还提供了包含一个或多个Formula (IIa)化合物的药物组合物。